Looking at AZ’s post-exposure mAb miss through a variant lens

AZ’s mAb cocktail miss in the post-exposure prophylaxis setting is surprising given its reported resilience to the variants behind Lilly’s withdrawals, but the rising Delta variant’s impact on the combo is still unknown.

The bulk of data suggests the best shot for antiviral mAbs is early in infection, and  Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Eli Lilly and Co. (NYSE:LLY) have shown positive late-stage data in the post-exposure prophylaxis setting...